



Resolution

of the Federal Joint Committee on an Amendment of the
Pharmaceuticals Directive:

Annex XII – Benefit Assessment of Medicinal Products with
New Active Ingredients according to Section 35a (SGB V)
Marstacimab (severe haemophilia A, ≥ 12 years, without
factor VIII inhibitors)

of 17 July 2025

At their session on 17 July 2025, the Federal Joint Committee (G-BA) resolved to amend the
Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009
(Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the
resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

- I. **Annex XII shall be amended in alphabetical order to include the active ingredient
Marstacimab as follows:**

Benefit assessment procedure comprises several resolutions.
Please note the current version of the Pharmaceuticals Directive/Annex XII.

Marstacimab

Resolution of: 17 July 2025

Entry into force on: 17 July 2025

Federal Gazette, BAnz AT DD. MM YYYY Bx

Therapeutic indication (according to the marketing authorisation of 18 November 2024):

Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with:

- severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or
- severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.

Therapeutic indication of the resolution (resolution of 17 July 2025):

Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors.

1. Additional benefit of the medicinal product in relation to the appropriate comparator therapy

Adults and adolescents 12 years of age and older, weighing at least 35 kg, with severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors for routine prophylaxis

Appropriate comparator therapy:

- Routine prophylaxis with human plasma-derived and recombinant coagulation factor VIII products or emicizumab

Extent and probability of the additional benefit of marstacimab compared to the appropriate comparator therapy:

An additional benefit is not proven.

Please note the current version of the Pharmaceutical Directive/Annex XII.
Benefit assessment procedure comprises several resolutions.

Study results according to endpoints:¹

Adults and adolescents 12 years of age and older, weighing at least 35 kg, with severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors for routine prophylaxis

No suitable data versus the appropriate comparator therapy were presented.

Summary of results for relevant clinical endpoints

Endpoint category	Direction of effect/ risk of bias	Summary
Mortality	n.a.	There are no assessable data.
Morbidity	n.a.	There are no assessable data.
Health-related quality of life	n.a.	There are no assessable data.
Side effects	n.a.	There are no assessable data.
Explanations: ↑: statistically significant and relevant positive effect with low/unclear reliability of data ↓: statistically significant and relevant negative effect with low/unclear reliability of data ↑↑: statistically significant and relevant positive effect with high reliability of data ↓↓: statistically significant and relevant negative effect with high reliability of data ↔: no statistically significant or relevant difference ∅: No data available. n.a.: not assessable		

2. Number of patients or demarcation of patient groups eligible for treatment

Adults and adolescents 12 years of age and older, weighing at least 35 kg, with severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors for routine prophylaxis

approx. 1,900 – 2,000 patients

3. Requirements for a quality-assured application

The requirements in the product information are to be taken into account. The European Medicines Agency (EMA) provides the contents of the product information (summary of product characteristics, SmPC) for Hymoviz (active ingredient: marstacimab) agreed upon in the context of the marketing authorisation at the following publicly accessible link (last access: 8 July 2025):

https://www.ema.europa.eu/en/documents/product-information/hymoviz-epar-product-information_en.pdf

¹ Data from the dossier assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) (A25-16) unless otherwise indicated.

Treatment with marstacimab should only be initiated and monitored by specialists experienced in treating patients with haemophilia A.

4. Treatment costs

Annual treatment costs:

Adults and adolescents 12 years of age and older, weighing at least 35 kg, with severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors for routine prophylaxis

Designation of the therapy	Annual treatment costs/ patient	
Medicinal product to be assessed:		
Marstacimab	Adults and adolescents 12 years of age and older	€ 370,067.86 – € 740,135.73
Appropriate comparator therapy:		
<i>recombinant blood coagulation factor VIII products</i>		
Damoctocog alfa pegol	Adults	€ 213,065.55 – € 298,537.15
	12 to < 18 years	€ 120,606.81 – € 256,369.43
Efmoctocog alfa	Adults	€ 208,512.09 – € 347,615.37
	12 to < 18 years	€ 119,200.24 – € 291,565.21
Lonoctocog alfa	Adults	€ 119,527.80 – € 470,407.41
	12 to < 18 years	€ 67,526.95 – € 383,886.93
Moroctocog alfa	Adults	€ 147,186.42 – € 427,551.88
	12 to < 18 years	€ 84,716.59 – € 362,804.53
Octocog alfa	Adults	€ 136,345.13 – € 388,328.69
	12 to < 18 years	€ 77,675.34 – € 332,841.10
Rurioctocog alfa pegol	Adults	€ 234,596.77 – € 303,615.21
	12 to < 18 years	€ 133,305.83 – € 251,131.45
Simoctocog alfa	Adults	€ 147,186.42 – € 427,551.88
	12 to < 18 years	€ 84,716.59 – € 362,804.53
Turoctocog alfa	Adults	€ 148,870.90 – € 376,467.31
	12 to < 18 years	€ 86,026.26 – € 317,351.24
Turoctocog alfa pegol	Adults	€ 263,121.12
	12 to < 18 years	€ 149,081.94 – € 232,075.47
<i>Human plasma-derived coagulation factor VIII products</i>		
Human plasma-derived products	Adults	€ 169,397.88 – € 504,550.45
	12 to < 18 years	€ 95,964.10 – € 431,720.18

Designation of the therapy	Annual treatment costs/ patient	
<i>IgG antibody</i>		
Emicizumab	Adults	€ 315,011.97 – € 328,919.81
	12 to < 18 years	€ 221,215.56 – € 270,922.86

Costs after deduction of statutory rebates (LAUER-TAXE®) as last revised: 1 July 2025)

Costs for additionally required SHI services: not applicable

5. Designation of medicinal products with new active ingredients according to Section 35a, paragraph 3, sentence 4 SGB V that can be used in a combination therapy with the assessed medicinal product

In the context of the designation of medicinal products with new active ingredients pursuant to Section 35a, paragraph 3, sentence 4 SGB V, the following findings are made:

Adults and adolescents 12 years of age and older, weighing at least 35 kg, with severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors for routine prophylaxis

- No medicinal product with new active ingredients that can be used in a combination therapy and fulfils the requirements of Section 35a, paragraph 3, sentence 4 SGB V.

The designation of combinations exclusively serves the implementation of the combination discount according to Section 130a SGB V between health insurance funds and pharmaceutical companies. The findings made neither restrict the scope of treatment required to fulfil the medical treatment mandate, nor do they make statements about expediency or economic feasibility.

6. Percentage of study participants at study sites within the scope of SGB V in accordance with Section 35a, paragraph 3, sentence 5 SGB V

The medicinal product Hympavzi is a medicinal product placed on the market from 1 January 2025.

The percentage of study participants in the clinical studies of the medicinal product conducted or commissioned by the pharmaceutical company in the therapeutic indication to be assessed who participated at study sites within the scope of SGB V (German Social Security Code) is < 5% (0.0%) of the total number of study participants.

The clinical studies of the medicinal product in the therapeutic indication to be assessed were therefore not conducted to a relevant extent within the scope of SGB V.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 17 July 2025.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 17 July 2025

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken

*Benefit assessment procedure comprises several resolutions.
Please note the current version of the Pharmaceuticals Directive/Annex XII.*